Primer: Mylan NV (MYL US) - Aug 2026
Mylan NV ceased to exist as an independent entity following its merger with Pfizer's Upjohn division in November 2020, creating Viatris Inc....
97 Views
Semaglutide Patent Expiry: The Next Big Unlock in Global Pharma
India's pharma industry prepares for Semaglutide patent expiry in 2026, offering a high-potential market opportunity for Indian players like Natco...
1.2k Views
Biocon: Can It Be Next Laurus Labs?
Biocon sees Mylan exit its stake, improving liquidity and refocusing on upcoming launches and deleveraging to prove biosimilar bet pays off.
136 Views
Para IV Winners and Losers - October 2018
This month’s Para IV developments suggest that there can be benefit for Amneal Pharmaceuticals Inc (AMRX US) in Xyren and Faslodex, Wockhardt Ltd...
549 Views
Para IV Winners and Losers - September 2018
This month’s Para IV developments suggest that there is likely to be benefit to Teva Pharmaceutical Sp Adr (TEVA US) on Vesicare, Soolantra and...
588 Views